[Study of cefamandole in neonatal purulent meningitis caused by E. coli (author's transl)]

Area of Science:

• Neonatal infectious diseases
• Pharmacology and therapeutics
• Bacterial meningitis treatment

Background:

• Neonatal meningitis poses a significant threat, particularly when caused by antibiotic-resistant bacteria like E. coli.
• Limited treatment options exist for severe neonatal infections, necessitating exploration of alternative antimicrobial agents.
• Cefamandole (CMD) is a cephalosporin antibiotic with potential utility in challenging bacterial infections.

Observation:

• A neonate diagnosed with purulent meningitis caused by E. coli, exhibiting resistance to ampicillin (ABPC), was treated with intravenous Cefamandole (CMD).
• The treatment involved a daily dose of 400 mg/kg of CMD administered via drip infusion.
• Gentamicin (GM) at 6 mg/kg/day was concurrently administered.

Findings:

• Cefamandole (CMD) demonstrated clinical effectiveness in treating the severe neonatal infection, purulent meningitis.
• No adverse effects or abnormal laboratory findings were reported during the treatment period.
• The combination therapy, including CMD and GM, was well-tolerated.

Implications:

• These findings suggest Cefamandole (CMD) is a potentially valuable therapeutic option for severe neonatal infections, including meningitis.
• CMD may be particularly useful in cases involving antibiotic-resistant pathogens like E. coli.
• Further clinical studies are warranted to confirm the safety and efficacy of CMD in a broader neonatal population.